These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 17024822

  • 21. [Value of quantitative examination of urine MUC1 in bladder transitional cell carcinoma].
    Xiang ST, Zhou SW, Guan W, Hu ZQ, Zhuang QY, Ye ZQ.
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):998-1000. PubMed ID: 16109559
    [Abstract] [Full Text] [Related]

  • 22. Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder.
    Passerotti CC, Bonfim A, Martins JR, Dall'Oglio MF, Sampaio LO, Mendes A, Ortiz V, Srougi M, Dietrich CP, Nader HB.
    Eur Urol; 2006 Jan; 49(1):71-5. PubMed ID: 16310928
    [Abstract] [Full Text] [Related]

  • 23. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
    Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z.
    Urol Int; 2008 Jan; 81(3):320-4. PubMed ID: 18931551
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
    van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, van Exsel AJ, Kirkels WJ, Bangma C, van der Kwast TH.
    Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J, Rodríguez-Martínez JJ, Barmadah SE, García Rodríguez J, Allende DM, Jalon A, Gonzalez R, Alvarez-Múgica M.
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lübbe L, Nowack R, Siegsmund M, Hoschke B.
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [Abstract] [Full Text] [Related]

  • 40. Analysis of hTERT expression in exfoliated cells from patients with bladder transitional cell carcinomas using SYBR green real-time fluorescence quantitative PCR.
    Xie XY, Yang X, Zhang JH, Liu ZJ.
    Ann Clin Biochem; 2007 Nov; 44(Pt 6):523-8. PubMed ID: 17961306
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.